ReviewMaedica2026
Prevalence and Odds of Bipolar Disorder in Patients with Multiple Sclerosis (MS): a Systematic Review and Meta-Analysis.
Review in Maedica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with multiple sclerosis (MS) suffer from a wide range of physical and psychiatric disorders. The literature shows an increased prevalence of bipolar disorder (BD) in MS patients. Objective: To estimate the pooled prevalence and odds of BD in patients with MS. Methods: PubMed, Scopus, EMBASE, Web of Science, PsycINFO and Google Scholar were systematically searched by two independent reviewers on March 1, 2024. Results: A literature search revealed 2228 records, of which 107 full texts were evaluated and finally, 34 studies remained for systematic review. The prevalence of BD in included studies ranged between 1% and 20%, and the estimated pooled prevalence was 3% (95% CI 2-4%) (I2=99%, p<0.001). The pooled prevalence of BD in patients with MS was estimated as 3% (95% CI 1-5%) in America and Europe continents (3%, 95% CI: 1-8%), and 2% (95% CI 1-3%) in Asia. The odds ratio (OR) of BD in MS cases ranged between 2.17 and 17.9, and the estimated pooled OR was 3.84 (95% CI 1.75-8.41) (I2=93%, P<0.01). Conclusions: The findings of this systematic review indicate that BD is relatively common among MS patients, who have an approximately threefold higher risk of developing BD than the general population. Subgroup analysis showed that the pooled prevalence of BD was lowest in Asia compared with Europe and the Americas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.